GLP-1 Drugs Improve Weight, Blood Sugar, and Heart Health in Children and Teens with Obesity or Diabetes

What the researchers found

Across 18 RCTs (1,402 participants; mean age 13.7 years; 59.3% female; median treatment 0.51 years), GLP-1 RAs vs. placebo showed:

- HbA1c: -0.44% (95% CI: -0.68% to -0.21%)

- Fasting glucose: -9.92 mg/dL (95% CI: -16.20 to -3.64)

- Body weight: -3.02 kg (95% CI: -4.98 to -1.06)

- BMI: -1.45 (95% CI: -2.40 to -0.49)

- BMI SDS: -0.20 (95% CI: -0.36 to -0.05)

- BMI percentile: -7.24% (95% CI: -12.97% to -1.51%)

- Systolic blood pressure: -2.73 mmHg (95% CI: -4.04 to -1.43)

- GI adverse events: increased (log RR 0.75)

- Suicidal ideation/behaviors: no significant difference vs. placebo

All efficacy outcomes reached statistical significance, supporting GLP-1 RAs for pediatric use.

Why it matters

As pediatric obesity reaches epidemic proportions, safe and effective pharmacotherapy options are desperately needed. This comprehensive meta-analysis from JAMA Pediatrics provides the strongest evidence to date that GLP-1 drugs work in young people, with a favorable safety profile regarding the critical concern of mental health side effects.

How the study worked

Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, Embase, and Cochrane CENTRAL from inception through February 2025. Included 18 RCTs comparing GLP-1 RAs to placebo in children and adolescents under 18 with obesity, overweight, prediabetes, or T2D. Two independent reviewers extracted data and assessed risk of bias using Cochrane RoB2. Random-effects inverse variance models were used for all analyses.

What this study cannot tell us

The median treatment duration was only about 6 months — long-term safety and efficacy in growing children remain unknown. The total sample size (1,402) is relatively modest for a meta-analysis. Effects on growth, puberty, bone health, and long-term mental health development were not assessed. Most trials studied a limited age range (mean 13.7 years), with less data for younger children.

How to read the evidence

This is a high-quality systematic review and meta-analysis of randomized controlled trials published in JAMA Pediatrics, representing the highest tier of clinical evidence. The Cochrane RoB2 tool was used for risk of bias assessment.

When this study was published

Published in 2025 with data through February 2025, this is the most current comprehensive evaluation of GLP-1 agonists in the pediatric population.

The bigger picture

This meta-analysis arrives at a critical moment as GLP-1 drugs are being approved for younger age groups and pediatric obesity is increasingly recognized as a serious health crisis. The data supports expanding these treatments to children and teens while addressing parental and clinical concerns about safety, particularly mental health effects that have received media attention.

Questions still open

• What are the long-term effects of GLP-1 agonists on growth and development in children?
• Do the benefits persist after discontinuation, or is there weight regain similar to adults?
• Should GLP-1 agonists be considered first-line pharmacotherapy for pediatric obesity?

Common questions

Read the original research

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

JAMA pediatrics, 179(12), 1308-1317

Citation

Kotecha, Pareeta; Huang, Wenxi; Yeh, Ya-Yun; Narvaez, Valerie Martino; Adirika, Darlene; Tang, Huilin; Bernier, Angelina V; Westen, Sarah C; Smith, Steven M; Bian, Jiang; Guo, Jingchuan. (2025). Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.. JAMA pediatrics, 179(12), 1308-1317. https://doi.org/10.1001/jamapediatrics.2025.3243